Latest News

ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...

A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.

Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.

Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.

Talquetamab plus teclistamab therapy for relapsed/refractory multiple myeloma demonstrated durable responses among patients, however, risk for grade 3 or 4 infections were higher than either therapy alone, according to a recent study.

On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.

Updated results from the phase 3 KATHERINE trial demonstrated that trastuzumab emtansine improved survival among previously treated patients with HER2-positive early breast cancer.

For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.

According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.

According to results from the phase 1b/2 MORPHEUS-Liver trial, the addition of tiragolumab to atezolizumab plus bevacizumab demonstrated promise among patients with previously untreated locally advanced or unresectable hepatocellular...